Consistency of patient versus investigator reporting of symptomatic adverse events (AEs) in international trials.
2020
38Background: FDA approved 3 androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer (nmCRPC) based on global randomized trials with control arms of placebo + ADT. Despi...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI